Lilly, Haisco Announce Tie-Up That May Be Worth Over $3 Billion
By Fabiana Negrin Ochoa and Colin Kellaher
Haisco Pharmaceutical Group has formed a licensing and research collaboration with Eli Lilly that is potentially worth more than $3 billion to the Chinese pharmaceutical company.
The Shenzhen-listed company will work with Lilly to develop innovative medicines across multiple therapeutic areas. Under the terms of the partnership announced Monday, Haisco will be eligible to receive up to $87 million in upfront and near-term payments, and as much as to $2.97 billion in downstream milestones, plus royalties on sales.
Haisco said in a statement that it will be responsible for the discovery and identification of up to five innovative target programs, while Lilly will lead studies, clinical development and commercialization.
The U.S. company will also get exclusive global rights to some of the programs, and exclusive rights outside mainland China, Hong Kong, Macau, and Taiwan for others.
The collaboration is the first license and research deal struck between Lilly and Haisco, which specializes in small-molecule innovative drugs, biologics and high-end generics.
Earlier, Haisco announced that its cipepofol injection received marketing approval from the U.S. Food and Drug Administration, making it the first China-originated innovative intravenous anesthetic to enter the global market.
It is now advancing commercialization in the U.S. and other regions through collaborations, and said it will consider starting a marketing authorization application for cipepofol in Europe.
Write to Fabiana Negrin Ochoa at fabiana.negrinochoa@wsj.com and Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 01, 2026 06:38 ET (10:38 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
The 10 Best and 10 Worst Months of All Time for the US Stock Market
United States